This document has not been cited yet.

1. Ali, M.M., Dowd, W.N., Classen, T., Mutter, R. & Novak, S.P. (2017) Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the National Survey of Drug Use and Health. Addictive Behaviors, 69, 65–77.
   Paper not yet in RePEc: Add citation now
   

2. Alpert, A., Powell, D. & Pacula, R.L. (2018) Supply‐side drug policy in the presence of substitutes: evidence from the introduction of abuse‐deterrent opioids. American Economic Journal: Economic Policy, 10(4), 1–35.

3. Baehren, D.F., Marco, C.A., Droz, D.E., Sinha, S., Callan, E.M. & Akpunonu, P. (2010) A statewide prescription monitoring program affects emergency department prescribing behaviors. Annals of Emergency Medicine, 56(1), 19–23.
   Paper not yet in RePEc: Add citation now
   

4. Bertrand, M., Duflo, E. & Mullainathan, S. (2004) How much should we trust differences‐in‐differences estimates? The Quarterly Journal of Economics, 119(1), 249–275.

5. Brady, J.E., Wunsch, H., DiMaggio, C., Lang, B.H., Giglio, J. & Li, G. (2014) Prescription drug monitoring and dispensing of prescription opioids. Public Health Reports, 129(2), 139–147.
   Paper not yet in RePEc: Add citation now
   
6. Branham, D.K. (2018) Time‐series analysis of the impact of prescription drug monitoring programs on heroin treatment admissions. Substance Use & Misuse, 53(4), 694–701.
   Paper not yet in RePEc: Add citation now
   

7. Buchmueller, T.C. & Carey, C. (2018) The effect of prescription drug monitoring programs on opioid utilization in Medicare. American Economic Journal: Economic Policy, 10(1), 77–112.

8. Buchmueller, T.C., Carey, C. & Mielle, G. (2020) How well do doctors know their patients? Evidence from a mandatory access prescription drug monitoring program. Health Economics, 29(9), 957–974. Available from: https://doi.org/10.1002/hec.4020.
   Paper not yet in RePEc: Add citation now
   

9. Cameron, A.C., Gelbach, J.B. & Miller, D.L. (2008) Bootstrap‐based improvements for inference with clustered errors. Review of Economics and Statistics, 90(3), 414–427. Available from: https://doi.org/10.1162/rest.90.3.414.

10. Carpenter, C.S., McClellan, C.B. & Rees, D.I. (2017) Economic conditions, illicit drug use, and substance use disorders in the United States. Journal of Health Economics, 52, 63–73.

11. Case, A. & Deaton, A. (2015) Rising morbidity and mortality in midlife among white non‐Hispanic Americans in the 21st century. Proceedings of the National Academy of Sciences of the United States of America, 112(49), 15078–15083.

12. Case, A. & Deaton, A. (2017) Mortality and morbidity in the 21st century. Brookings Papers on Economic Activity. 2017, 397–476.

13. Centers for Disease Control and Prevention. (2020) Synthetic opioid overdose data: drug overdose. CDC Injury Center. Available at: https://www.cdc.gov/drugoverdose/data/fentanyl.html.
    Paper not yet in RePEc: Add citation now
    
14. Chang, H.‐Y., Lyapustina, T., Rutkow, L., Daubresse, M., Richey, M., Faul, M., et al. (2016) Impact of prescription drug monitoring programs and pill mill laws on high‐risk opioid prescribers: A comparative interrupted time series analysis. Drug and Alcohol Dependence, 165, 1–8.
    Paper not yet in RePEc: Add citation now
    
15. CMS. (2015) Opioid morphine equivalent conversion factors. Available at: https://www.cms.gov/Medicare/PrescriptiDrug‐Coverage/prescriptionDrugCovContra/Downloads/Opioid‐Morphine‐EQ‐Conversion‐Factors‐March‐2015.pdf.
    Paper not yet in RePEc: Add citation now
    
16. CNN. (2017) CVS will limit opioid prescriptions to 7 days. Available at: https://www.cnn.com/2017/09/22/health/cvs‐prescription‐restrictions‐opioids‐bn/index.html.
    Paper not yet in RePEc: Add citation now
    
17. Cochran, B.N., Flentje, A., Heck, N.C., Van Den Bos, J., Perlman, D., Torres, J., et al. (2014) Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially‐insured individuals. Drug and Alcohol Dependence, 138, 202–208.
    Paper not yet in RePEc: Add citation now
    

18. Dave, D., Cotet‐Grecu, A. & Saffer, H. (2018) Mandatory access prescription drug monitoring programs and prescription drug abuse. Journal of Policy Analysis and Management, 38(1).

19. Delcher, C., Wagenaar, A.C., Goldberger, B.A., Cook, R.L. & Maldonado‐Molina, M.M. (2015) Abrupt decline in oxycodone‐caused mortality after implementation of Floridas Prescription Drug Monitoring Program. Drug and Alcohol Dependence, 150, 63–68.
    Paper not yet in RePEc: Add citation now
    

20. Donald, S.G. & Lang, K. (2007) Inference with difference‐in‐differences and other panel data. Review of Economics and Statistics, 89(2), 221–233.

21. Donner, B., Zenz, M., Tryba, M., & Strumpf, M. (1996) Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain, 64(3), 527–534.
    Paper not yet in RePEc: Add citation now
    
22. Dowell, D., Haegerich, T.M. & Chou, R. (2016) CDC guideline for prescribing opioids for chronic pain ‐ United States, 2016. MMWR Recommendations and Reports, 65(1), 1–49. Available from: https://doi.org/10.15585/mmwr.rr6501e1.
    Paper not yet in RePEc: Add citation now
    
23. Ellyson, A., Grooms, J. & Ortega, A. (2018) Flipping the script: the effect of prescription drug monitoring programs on opioid prescribing behavior. Draft manuscript.
    Paper not yet in RePEc: Add citation now
    

24. Evans, W.N., Lieber, E.M.J. & Power, P. (2019) How the reformulation of oxycontin ignited the heroin epidemic. The Review of Economics and Statistics, 101(1), 1–15.

25. Gomes, T., Tadrous, M., Madani, M.M., Paterson, J.M. & Juurlink, D.N. (2018) The burden of opioid‐related mortality in the United States. JAMA Network Open, 1(2), e180217. Available from: https://doi.org/10.1001/jamanetworkopen.2018.0217.
    Paper not yet in RePEc: Add citation now
    
26. Gupta, S. & Al Achkar, M. (2017) Fighting the opioid crisis: Lessons from Kentucky. Mimeo. Available from: https://doi.org/10.2105/AJPH.2017.304265. Available at: https://iu.box.com/s/2s605yzil5d03b8oseqv4xno527l02fs.
    Paper not yet in RePEc: Add citation now
    
27. Haffajee, R.L., Jena, A.B. & Weiner, S.G. (2015) Mandatory use of prescription drug monitoring programs. JAMA, 313(9), 891–892.
    Paper not yet in RePEc: Add citation now
    
28. Henry J. Kaiser Family Foundation. (2017) Opioid overdose deaths by race/ethnicity. Available at: https://www.kff.org/other/state‐indicator/opioid‐overdose‐death‐rates/.
    Paper not yet in RePEc: Add citation now
    

29. Hollingsworth, A., Ruhm, C.J. & Simon, K. (2017) Macroeconomic conditions and opioid abuse. Journal of Health Economics, 56, 222–233.

1. Insurance Coverage and Provision of Opioid Treatment: Evidence from Medicare. (2023). Simon, Kosali ; Maclean, Johanna ; Cantor, Jonathan H ; Taylor, Erin ; Agniel, Denis.
   In: NBER Working Papers.
   RePEc:nbr:nberwo:31884.

   Full description at Econpapers || Download paper

2. Flipping the script: The effects of opioid prescription monitoring on specialty‐specific provider behavior. (2022). Grooms, Jevay ; Ellyson, Alice M ; Ortega, Alberto.
   In: Health Economics.
   RePEc:wly:hlthec:v:31:y:2022:i:2:p:297-341.

   Full description at Econpapers || Download paper

3. Lethal Unemployment Bonuses? Substitution and Income Effects on Substance Abuse, 2020-21. (2022). Mulligan, Casey.
   In: NBER Working Papers.
   RePEc:nbr:nberwo:29719.

   Full description at Econpapers || Download paper

4. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2022). Liebert, Helge ; Sherry, Tisamarie B ; Balestra, Simone ; Maestas, Nicole.
   In: IZA Discussion Papers.
   RePEc:iza:izadps:dp15221.

   Full description at Econpapers || Download paper

5. Opioids and the Labor Market. (2022). Schweitzer, Mark ; Fee, Kyle ; Aliprantis, Dionissi.
   In: Working Papers.
   RePEc:fip:fedcwq:180702.

   Full description at Econpapers || Download paper

6. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2022). Liebert, Helge ; Sherry, Tisamarie B ; Balestra, Simone ; Maestas, Nicole.
   In: CESifo Working Paper Series.
   RePEc:ces:ceswps:_9704.

   Full description at Econpapers || Download paper

7. Are prescription drug monitoring laws effective for all? Evidence from administrative data. (2022). Gupta, Sumedha ; al Achkar, Morhaf ; Ray, Bradley.
   In: Contemporary Economic Policy.
   RePEc:bla:coecpo:v:40:y:2022:i:1:p:28-47.

   Full description at Econpapers || Download paper

8. Information Avoidance and Celebrity Exposure: The Effect of Magic Johnson on AIDS Diagnoses and Mortality in the U.S.. (2021). Martin, Joshua ; Rodriguez, Zachary ; Cardazzi, Alexander.
   In: Working Papers.
   RePEc:wvu:wpaper:21-04.

   Full description at Econpapers || Download paper

9. Prescription drug monitoring programs, opioid abuse, and crime. (2021). Horn, Brady ; Deza, Monica ; Dave, Dhaval.
   In: Southern Economic Journal.
   RePEc:wly:soecon:v:87:y:2021:i:3:p:808-848.

   Full description at Econpapers || Download paper

10. The complementarity of drug monitoring programs and health IT for reducing opioid‐related mortality and morbidity. (2021). Wang, Lucy Xiaolu.
    In: Health Economics.
    RePEc:wly:hlthec:v:30:y:2021:i:9:p:2026-2046.

    Full description at Econpapers || Download paper

11. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2021). Liebert, Helge ; Sherry, Tisamarie B ; Balestra, Simone ; Maestas, Nicole.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:29596.

    Full description at Econpapers || Download paper

12. Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation. (2021). Mulligan, Casey.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:29574.

    Full description at Econpapers || Download paper

13. Illicit Drugs and the Decline of the Middle Class. (2021). Strulik, Holger ; Grossmann, Volker.
    In: IZA Discussion Papers.
    RePEc:iza:izadps:dp14035.

    Full description at Econpapers || Download paper

14. Labor Market Effects of the Oxycodone-Heroin Epidemic. (2021). Garcia, Daniel ; Cho, David ; Weingarden, Alison E.
    In: Finance and Economics Discussion Series.
    RePEc:fip:fedgfe:2021-25.

    Full description at Econpapers || Download paper

15. Thinking outside the box: The cross-border effect of tax cuts on R&D. (2021). Schwab, Thomas ; Todtenhaupt, Maximilian.
    In: Journal of Public Economics.
    RePEc:eee:pubeco:v:204:y:2021:i:c:s0047272721001729.

    Full description at Econpapers || Download paper

16. Is the rise in illicit opioids affecting labor supply and disability claiming rates?. (2021). Powell, David ; Park, Sujeong.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:76:y:2021:i:c:s0167629621000151.

    Full description at Econpapers || Download paper

17. Can policy affect initiation of addictive substance use? Evidence from opioid prescribing. (2021). Hollingsworth, Alex ; Nguyen, Thuy ; Simon, Kosali ; Sacks, Daniel W.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:76:y:2021:i:c:s0167629620310432.

    Full description at Econpapers || Download paper

18. Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences. (2021). Kim, Bo Kyung.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:75:y:2021:i:c:s0167629620310547.

    Full description at Econpapers || Download paper

19. Illicit drugs and the decline of the middle class. (2021). Strulik, Holger ; Grossmann, Volker.
    In: Journal of Economic Behavior & Organization.
    RePEc:eee:jeborg:v:183:y:2021:i:c:p:718-743.

    Full description at Econpapers || Download paper

20. Designing interagency responses to wicked problems: Creating a common, cross-agency understanding. (2021). Sydelko, Pamela ; Midgley, Gerald ; Espinosa, Angela.
    In: European Journal of Operational Research.
    RePEc:eee:ejores:v:294:y:2021:i:1:p:250-263.

    Full description at Econpapers || Download paper

21. Can electronic prescribing mandates reduce opioid-related overdoses?. (2021). Powell, David ; Abouk, Rahi.
    In: Economics & Human Biology.
    RePEc:eee:ehbiol:v:42:y:2021:i:c:s1570677x21000241.

    Full description at Econpapers || Download paper

22. The Intended and Unintended Effects of Opioid Policies on Prescription Opioids and Crime. (2021). Giua, Ludovica ; Ludovica, Giua ; Claudio, Deiana.
    In: The B.E. Journal of Economic Analysis & Policy.
    RePEc:bpj:bejeap:v:21:y:2021:i:2:p:751-792:n:11.

    Full description at Econpapers || Download paper

23. Breaking the Crystal Methamphetamine Economy: Illegal Drugs, Supply‐side Interventions and Crime Responses. (2021). d'Este, Rocco.
    In: Economica.
    RePEc:bla:econom:v:88:y:2021:i:349:p:208-233.

    Full description at Econpapers || Download paper

24. When Innovation Goes Wrong: Technological Regress and the Opioid Epidemic. (2021). Glaeser, Edward L ; Cutler, David M.
    In: Journal of Economic Perspectives.
    RePEc:aea:jecper:v:35:y:2021:i:4:p:171-96.

    Full description at Econpapers || Download paper

25. How well do doctors know their patients? Evidence from a mandatory access prescription drug monitoring program. (2020). Buchmueller, Thomas C ; Meille, Giacomo ; Carey, Colleen M.
    In: Health Economics.
    RePEc:wly:hlthec:v:29:y:2020:i:9:p:957-974.

    Full description at Econpapers || Download paper

26. Drugs on the Web, Crime in the Streets - The Impact of Dark Web Marketplaces on Street Crime. (2020). Zambiasi, Diego.
    In: Working Papers.
    RePEc:ucn:wpaper:202025.

    Full description at Econpapers || Download paper

27. Drugs on the Web, Crime in the Streets. The impact of Dark Web marketplaces on street crime. (2020). Zambiasi, Diego.
    In: Working Papers.
    RePEc:ucd:wpaper:202009.

    Full description at Econpapers || Download paper

28. Is the Rise in Illicit Opioids Affecting Labor Supply and Disability Claiming Rates?. (2020). Powell, David ; Park, Sujeong.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27804.

    Full description at Econpapers || Download paper

29. Competitive Effects of Federal and State Opioid Restrictions: Evidence from the Controlled Substance Laws. (2020). Simon, Kosali ; Gupta, Sumedha ; Nguyen, Thuy D ; Freeman, Patricia R.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27520.

    Full description at Econpapers || Download paper

30. Three Myths about Federal Regulation. (2020). Mulligan, Casey ; McLaughlin, Patrick A.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27233.

    Full description at Econpapers || Download paper

31. Paid sick-leave and physical mobility: Evidence from the United States during a pandemic. (2020). Simon, Kosali ; Pesko, Michael ; Maclean, Johanna ; Andersen, Martin.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27138.

    Full description at Econpapers || Download paper

32. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses. (2020). Powell, David ; Pacula, Rosalie.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26988.

    Full description at Econpapers || Download paper

33. Prices and Federal Policies in Opioid Markets. (2020). Mulligan, Casey.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26812.

    Full description at Econpapers || Download paper

34. The Intergenerational Transmission of Opioid Dependence: Evidence from Administrative Data. (2020). Halla, Martin ; Ahammer, Alexander.
    In: Economics working papers.
    RePEc:jku:econwp:2020-10.

    Full description at Econpapers || Download paper

35. The Intergenerational Transmission of Opioid Dependence: Evidence from Administrative Data. (2020). Halla, Martin ; Ahammer, Alexander.
    In: IZA Discussion Papers.
    RePEc:iza:izadps:dp13395.

    Full description at Econpapers || Download paper

36. Retail Pharmacies and Drug Diversion during the Opioid Epidemic. (2020). Zhang, Xuan ; Janssen, Aljoscha.
    In: Working Paper Series.
    RePEc:hhs:iuiwop:1373.

    Full description at Econpapers || Download paper

37. The relationship of opioid prescriptions and the educational performance of children. (2020). Ozturk, Orgul ; Gordanier, John M ; Cotti, Chad D.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:265:y:2020:i:c:s0277953620306250.

    Full description at Econpapers || Download paper

38. Umbrella branding in pharmaceutical markets. (2020). Suppliet, Moritz.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:73:y:2020:i:c:s0167629619303856.

    Full description at Econpapers || Download paper

39. How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D. (2020). Powell, David ; Pacula, Rosalie ; Taylor, Erin.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:71:y:2020:i:c:s0167629619303029.

    Full description at Econpapers || Download paper

40. Prices and Federal Policies in Opioid Markets. (2020). Mulligan, Casey B.
    In: Working Papers.
    RePEc:bfi:wpaper:2020-10.

    Full description at Econpapers || Download paper

41. Shackling the Identification Police?. (2019). Ruhm, Christopher.
    In: Southern Economic Journal.
    RePEc:wly:soecon:v:85:y:2019:i:4:p:1016-1026.

    Full description at Econpapers || Download paper

42. Health insurance and opioid deaths: Evidence from the Affordable Care Act young adult provision. (2019). Wettstein, Gal.
    In: Health Economics.
    RePEc:wly:hlthec:v:28:y:2019:i:5:p:666-677.

    Full description at Econpapers || Download paper

43. Adverse health effects of abuse‐deterrent opioids: Evidence from the reformulation of OxyContin. (2019). Beheshti, David.
    In: Health Economics.
    RePEc:wly:hlthec:v:28:y:2019:i:12:p:1449-1461.

    Full description at Econpapers || Download paper

44. How do Opioid Prescribing Restrictions Affect Pharmaceutical Promotion? Lessons from the Mandatory Access Prescription Drug Monitoring Programs. (2019). Simon, Kosali ; Bradford, W. David ; Nguyen, Thuy D.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26356.

    Full description at Econpapers || Download paper

45. Can Policy Affect Initiation of Addictive Substance Use? Evidence from Opioid Prescribing. (2019). Simon, Kosali ; Hollingsworth, Alex ; Nguyen, Thuy D ; Sacks, Daniel W.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:25974.

    Full description at Econpapers || Download paper

46. A novel supply-side measure to combat abuse of addictive prescription drugs. (2019). Ahammer, Alexander.
    In: Economics working papers.
    RePEc:jku:econwp:2019_11.

    Full description at Econpapers || Download paper

47. Digital Waste? Unintended Consequences of Health Information Technology. (2019). Nurminen, Mikko ; Laine, Liisa ; Kortelainen, Mika ; Böckerman, Petri ; Bockerman, Petri ; Saxell, Tanja.
    In: IZA Discussion Papers.
    RePEc:iza:izadps:dp12275.

    Full description at Econpapers || Download paper

48. Digital Waste? Unintended Consequences of Health Information Technology. (2019). Nurminen, Mikko ; Laine, Liisa ; Kortelainen, Mika ; Böckerman, Petri ; Saxell, Tanja ; Bockerman, Petri.
    In: Working Papers.
    RePEc:fer:wpaper:117.

    Full description at Econpapers || Download paper

49. Drivers of the fatal drug epidemic. (2019). Ruhm, Christopher.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:64:y:2019:i:c:p:25-42.

    Full description at Econpapers || Download paper

50. Shackling the Identification Police?. (2018). Ruhm, Christopher.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:25320.

    Full description at Econpapers || Download paper

Report date: 2025-09-21 06:26:47 || Missing content? Let us know